[quote]trailer36 wrote:
Gnostic,
be careful on this, Cy has said that these types of PCT supps do not work as they are touted to. if i was you i would add the ergomax and stick to the tried and true nolva/clomid for PCT.[/quote]
Thx for the headsup, Trailer. It appears that Novedex XT has some descent supporting data behind it.
Poster 43
Ziegenfuss T.N., Mendel R.W., and Hofheins J.E. Safety and Efficacy of a Commercially-Available, Naturally-Occurring, Aromatase Inhibitor in Healthy Men. Ohio Research Group of
Exercise Science and Sports Nutrition. Wadsworth, Ohio 44281, USA.
tim@ohioresearchgroup.com
Rationale: In healthy eugonadal men, it is known that blocking estrogen formation stimulates the hypothalamic-pituitary-testicular (HPT) axis to increase in vivo androgen production. Recently, a new class of dietary supplements has appeared that claim to inhibit the aromatase enzyme (i.e.,
decrease the transformation of aromatizable androgen[androstenedione, DHEA, testosterone] into estrogens [estriol, estrone, estradiol]), leading to an increase in androgen and testosterone formation.
Purpose: As the first step in a series of experiments on a popular, over-the-counter aromatase inhibitor, the purpose of this pilot study was to examine the effects of Novedex XT?
(NOV-XT) administration on selected hormonal responses (total testosterone [TT], bioavailable testosterone [BT] and estradiol [E2]), as well as serum and plasma markers of renal, hepatic, and hematological function.
Methods: Using an open-label, proof-of-concept design, five eugonadal men (mean ? SD age, height, weight, body fat: 31.0 ? 5.3 yr, 177.0 ? 3.8 cm, 86.6 ? 8.7 kg, 15.2 ? 5.4 %) ingested 4 capsules of NOV-XT prior to bed for 28 consecutive days. According to the manufacturer, each capsule of NOV-XT contains 60 mg of a proprietary blend of three naturally occurring aromatase inhibitors: 6, 17-keto-etiocholene-3-ol tetrahydropyranol ether, 3, 17-ketoetiochol-triene, and 3?,5,7-trihydroxy-4?-methoxyflavone (supplements were provided by an FDA registered, pharmaceutically licensed manufacturer; confirmation by an external laboratory is pending). Blood samples obtained at baseline (prior to supplementation), and at weekly intervals the reafter for 28 days, were analyzed for TT, BT, and E2 by radioimmunometric and chemilluminetric assays.
Subjects were required to maintain their normal dietary and training patterns during the study. All blood samples were obtained at the same time of day (0700-0900) to
minimize diurnal variation. Hormone concentrations were statistically analyzed by ANOVA and Journal of the International Society of Sports Nutrition. 2 (1):1-30, 2005.
(www.sportsnutritionsociety.org)
29 Tukey?s HSD post-hoc test. Dependent t-tests were used to compare changes in blood chemistries.
Statistical significance was accepted at p<0.05. Results: Compared to baseline, NOV-XT administration rapidly and significantly increased TT and BT. Mean changes from baseline for TT(Figure 1) after one, two, three, and four weeks of NOV-XT administration were: +145%
(p<0.006), +183% (p<0.0005), +232% (p<0.0002), and +240% (p<0.0002), respectively. Mean changes from baseline for BT (Figure 2) after one, two, three, and four weeks of NOV-XT
administration were: +300% (p<0.01), +402% (p<0.0009), +511% (p<0.0002), and +528%(p<0.0002), respectively.
Despite these large increases in TT and BT, no significant aromatization
to estradiol was observed (i.e., E2 concentrations remained 3-6 pg/mL below baseline at all time
points). No statistically significant changes in clinical blood chemistries (fasting glucose, BUN,
creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase,
sodium, potassium, chloride, calcium, albumin, globulin, CO2, total protein, total cholesterol,
triglycerides, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol) or systemic hemodynamics
(heart rate, systolic blood pressure, diastolic blood pressure) were observed, nor were any adverse events reported in the study.
Conclusions: Within the framework of the current experimental design, these preliminary data indicate that four weeks of NOV-XT administration significantly elevates serum TT and BT, likely via the inhibition of estradiol formation and the shifting of the HPT axis towards androgen/testosterone production. In healthy, eugonadal men, supplementation with NOV-XT does
not appear to result in any deleterious effects on blood chemistry or systemic hemodynamics.
Ongoing research is being conducted to confirm and refine these results in a larger sample size, as well as examine the impact of NOV-XT on androgenic and estrogenic metabolites, body
composition, and muscular performance.